Moderna’s success with its Covid-19 vaccine has busted the dam open on a range of potential mRNA therapeutics — and now the biotech is pushing to keep the cutting edge in-house. A new partnership with standout antibody discovery outfit AbCellera could help keep the ball in the competition’s court.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,